Comparative Pharmacology
Head-to-head clinical analysis: ACAMPROSATE CALCIUM versus CAMPRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACAMPROSATE CALCIUM versus CAMPRAL.
ACAMPROSATE CALCIUM vs CAMPRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Modulates glutamatergic neurotransmission by antagonizing NMDA receptors and potentiating GABAergic activity, restoring the balance between neuronal excitation and inhibition in alcohol dependence.
Acamprosate (calcium acetylhomotaurinate) is thought to stabilize the chemical balance in the brain that is altered by alcohol dependence. Its exact mechanism is unknown, but it is believed to restore the balance of inhibitory (GABA) and excitatory (glutamate) neurotransmission, reducing the physiological symptoms of alcohol withdrawal and craving.
666 mg (two 333 mg tablets) orally three times daily, total daily dose 1998 mg. Initiate as soon as possible after abstinence is achieved; maintain for 12 months.
666 mg (three 333 mg tablets) orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 20–30 hours; steady-state reached after 5–7 days.
Terminal elimination half-life is 20-30 hours (mean 23 hours), supporting twice-daily dosing; steady-state achieved after 5-7 days
Renal excretion as unchanged drug: 90%; fecal: <1%; minor biliary elimination.
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<10%)
Category C
Category C
Alcohol Deterrent
Alcohol Deterrent